Figure 6.
Therapeutic treatment with oral MH retards tumor growth in an IFNγ-dependent manner. Normal C57BL/6 (A) or IFNγ-deficient (B) mice were implanted with tumor cells and were orally gavaged daily starting on day 3 post implantation with 70% SC or 70% MH for 3 consecutive weeks. Each data point represents the mean ± SEM of the indicated mice within each experimental group, pooled from 2 independent experiments. Asterisks denote statistically significant differences between the SC-treated and MH-treated groups. p values were calculated using 2-way ANOVA, *** (p ≤ 0.001).